| Document Date: 2014-09-18 02:30:59
Open Document File Size: 173,12 KBShare Result on Facebook
City Civacir Albuferon Nexavar / / Company Tibotec Pharmaceuticals Ltd. / Roche / Pharmasset / InterMune / Schering / Vertex / Idera Pharmaceuticals / TLR Agonist Anadys Pharmaceuticals / Santaris Pharma / Test Population Laboratory / Polymerase Inhibitor Anadys Pharmaceuticals / / Continent Europe / / Country Taiwan / Switzerland / Netherlands / Italy / France / United States / / Event FDA Phase / Business Partnership / Earnings Announcement / / IndustryTerm treatment of hepatitis C / HCV treatment / / MedicalCondition HIV / HCV genotype 1 / hepatitis C / hepatitis C. A / HCV genotype 2 / orphan diseases / disease / hepatitis C. For / HCV / HCV infection / anemia / HCV RNA / / Organization Food and Drug Administration / United Nations / FDA / / Position General / Editor-in-Chief / Governor / / Product Infergen / Alinia / PegIntron / PEGInterferon / Copegus / GS / ribavirin / Pegasys / CTS / PF-00868554 / R7128 / IMO-2125 / ABT-333 / 1 Drug / VCH-916 / TMC435350 / Name Drug / SPC3649 / ANA598 / VX-500 / interferon / ANA773 / HCV / TMC435350-C201 / SVR12 / VX-813 / MF59 / ITMN-191 / PHX1766 / A3AR / Phase IV HCV/MF59 Oral / CYT107 / IDX184 / PYN17 / / Technology alpha / pharmacokinetics / genotype / drug development / / URL www.allp.com / www.clincialtrials.gov / /
SocialTag |
Hepatitis C Treatments in Current Clinical Development--December 8, 2008